Print  |  Close

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Active: Yes
Cancer Type: Hematopoietic Malignancies
Multiple Myeloma
Plasma cell neoplasm
NCT ID: NCT05050097
Trial Phases: Phase I Protocol IDs: CR108946 (primary)
Eligibility: 18 Years and older, Male and Female Study Type: Treatment
Study Sponsor: Janssen Research & Development, LLC
NCI Full Details:


The purpose of this study is to characterize the safety and tolerability of talquetamab when
administered in different combination regimens and to identify the safe dose(s) of
talquetamab combination regimens.
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.